Search research articles
Contact Us
Filters
Showing results (541-550 of 627) with videos related to
Page
of 63
Sort By:
Diabetes, Obesity & Metabolism
|
March 26, 2021
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial
Clare Arnott, Jing-Wei Li, Christopher P Cannon, et al.
Journal of the American College of Cardiology
|
July 11, 2020
Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI
Guillaume Marquis-Gravel, Frederik Dalgaard, Aaron D Jones, et al.
American Heart Journal
|
November 12, 2019
Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation
Zak Loring, Peter Shrader, Larry A Allen, et al.
European Heart Journal
|
August 30, 2024
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial
Kenneth W Mahaffey, Katherine R Tuttle, Mustafa Arici, et al.
BMJ Open Diabetes Research & Care
|
June 13, 2023
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
David M Charytan, Kenneth W Mahaffey, Meg J Jardine, et al.
Circulation
|
April 8, 2022
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
Brendon L Neuen, Megumi Oshima, Rajiv Agarwal, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
November 20, 2020
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m<sup>2</sup>: Subgroup Analysis of the Randomized CREDENCE Trial
George Bakris, Megumi Oshima, Kenneth W Mahaffey, et al.
Journal of the American Heart Association
|
February 18, 2018
Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
Benjamin A Steinberg, Peter Shrader, Karen Pieper, et al.
Journal of the American Heart Association
|
July 9, 2018
International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post-MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee
Yejin Mok, Shoshana H Ballew, Lori D Bash, et al.
Heart (British Cardiac Society)
|
September 20, 2018
B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation
Taku Inohara, Sunghee Kim, Karen Pieper, et al.
Page
of 63
Search research articles
Search
Showing results (541-550 of 627) with videos related to
Sort By:
Page
of 63
Diabetes, Obesity & Metabolism
|
March 26, 2021
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial
Clare Arnott, Jing-Wei Li, Christopher P Cannon, et al.
Journal of the American College of Cardiology
|
July 11, 2020
Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI
Guillaume Marquis-Gravel, Frederik Dalgaard, Aaron D Jones, et al.
American Heart Journal
|
November 12, 2019
Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation
Zak Loring, Peter Shrader, Larry A Allen, et al.
European Heart Journal
|
August 30, 2024
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial
Kenneth W Mahaffey, Katherine R Tuttle, Mustafa Arici, et al.
BMJ Open Diabetes Research & Care
|
June 13, 2023
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
David M Charytan, Kenneth W Mahaffey, Meg J Jardine, et al.
Circulation
|
April 8, 2022
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
Brendon L Neuen, Megumi Oshima, Rajiv Agarwal, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
November 20, 2020
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m<sup>2</sup>: Subgroup Analysis of the Randomized CREDENCE Trial
George Bakris, Megumi Oshima, Kenneth W Mahaffey, et al.
Journal of the American Heart Association
|
February 18, 2018
Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
Benjamin A Steinberg, Peter Shrader, Karen Pieper, et al.
Journal of the American Heart Association
|
July 9, 2018
International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post-MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee
Yejin Mok, Shoshana H Ballew, Lori D Bash, et al.
Heart (British Cardiac Society)
|
September 20, 2018
B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation
Taku Inohara, Sunghee Kim, Karen Pieper, et al.
Page
of 63